Preventive Health After 65: What Actually Moves the Needle

Preventive priorities shift with age. In your 40s and 50s, cancer screening and cardiometabolic risk factors dominate. Past 65, three additional things move to the top of the list because they drive a disproportionate share of disability and loss of independence: bone density, fall risk, and medication burden.

Bone density: a screening most people underrate

The U.S. Preventive Services Task Force gives a "B" grade — meaning there is moderate certainty of moderate net benefit — to osteoporosis screening in women 65 or older, using DXA bone mineral density testing. It's a more common condition than most people assume: based on U.S. national survey data cited in the USPSTF's own review, age-adjusted osteoporosis prevalence is 12.6% among adults 50 and older, rising to 27.1% in women and 5.7% in men once you look specifically at the 65-and-older group. For postmenopausal women younger than 65 with one or more risk factors — low body weight, a parent's hip fracture, smoking, or heavy alcohol use — the USPSTF recommends a two-step approach: a clinical risk assessment tool first, then DXA screening if that assessment indicates increased risk.

Fall risk: the intervention with an outsized return

The USPSTF recommends exercise interventions to prevent falls in community-dwelling adults 65 or older who are at increased risk, and selectively offering multifactorial interventions based on fall history, comorbidities, and personal preference. This isn't a minor recommendation — falls are among the most common preventable causes of disability in this age group, and unlike many risk factors, fall risk responds directly and measurably to targeted exercise programs (balance and strength training in particular).

Medication review: the overlooked lever

A 2023 European position paper from the EuGMS Task and Finish Group on Fall-risk-increasing Drugs, published in European Geriatric Medicine, makes a case that's easy to miss in routine care: many commonly prescribed medications — sedatives, certain blood pressure drugs, some antidepressants — measurably raise fall risk, especially in combination. The paper recommends that fall risk and medication burden be assessed together, with structured deprescribing (reducing or discontinuing drugs that are no longer providing net benefit) built into routine falls-prevention care rather than treated as a separate, optional step.

The practical takeaway is straightforward but rarely acted on: an annual review of every medication and supplement someone over 65 is taking — prescription and over-the-counter — specifically screened against known fall-risk-increasing drug classes, is one of the highest-leverage, lowest-cost preventive actions available at this life stage.

How Aeonix fits

Bone density and fall-risk assessment sit outside a standard blood panel, but the biomarker side of healthy aging — bone turnover markers, vitamin D status, inflammatory markers, and metabolic indicators tied to frailty risk — is exactly what comprehensive lab testing is built to surface early, well before symptoms appear.